
CRGX
Healthcare · Biotechnology · $216.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2025
EPS trend, 90 days to now · +96.6% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2025 | Time not confirmed | -1.29 | 0.00 | +100.0% |
| Aug 20, 2025 | Time not confirmed | -1.30 | -1.04 | +20.0% |
| May 14, 2025 | Time not confirmed | -1.17 | -1.77 | -51.3% |
| Mar 21, 2025 | Time not confirmed | -1.68 | -0.95 | +43.5% |
| Nov 13, 2024 | Time not confirmed | -1.61 | -0.88 | +45.3% |
| Aug 13, 2024 | Time not confirmed | -1.41 | -1.02 | +27.7% |
| May 14, 2024 | After the close | -1.05 | -0.87 | +17.1% |
| Mar 21, 2024 | After the close | -1.44 | -1.49 | -3.5% |
| Dec 13, 2023 | After the close | -2.78 | -47.37 | -1604.0% |
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution designed to effectively…